

## CURRICULUM VITAE

**John M. Maggiano, M.D.**  
*Fellow, American Academy of Ophthalmology*  
*Qualified Medical Examiner, State of California*  
CA Medical License #G32444

Mailing/Contact Address:  
Orange County Retina Medical Group  
1200 North Tustin Avenue, Suite 140  
Santa Ana, California 92705  
714-972-8432

### PROFESSIONAL PRACTICE AFFILIATIONS

---

Orange County Retina Medical Group  
Physician/Surgeon/Founding Partner/Clinical Trial Investigator  
1/1/1979 – Present

1200 North Tustin Avenue	Suite 140	Santa Ana, CA 92705	714-972-8432
1200 North Tustin Avenue	Suite 100	Santa Ana, CA 92705	714-972-8432
24022 Calle de la Plata	Suite 475	Laguna Hills, CA 92653	949-581-3618
320 Superior Avenue	Suite 160	Newport Beach, CA 92663	949-646-3242
333 W. Bastanchury Road	Suite 200	Fullerton, CA 92835	714-451-0801
31451 Rancho Viejo Road	Suite 101	San Juan Capistrano, CA 92675	949-496-0611

### EDUCATION AND TRAINING

---

#### **Vitreo-Retinal Fellowship**

The Eye Institute of The Medical College of Wisconsin, Milwaukee, Wisconsin, 1977-1978  
Thomas M. Aaberg, MD, Director, Retinal Section / Richard Schultz, MD, Chief

#### **Medical Retina and Retinal Physiology Fellowship**

Post-Doctoral Fellowship in Medical and Hereditary Retinal Diseases  
National Institutes of Health, PHS Grant #EY 24-19  
Gerald A. Fishman, MD, Preceptor / Morton F. Goldberg, MD, Chief  
Eye and Ear Infirmary, University of Illinois, Chicago, Illinois, 1976-1977

#### **Residency in Ophthalmology**

Loyola University Affiliated Hospital, Chicago, Illinois  
James E. McDonald, MD, Chief, 1973-1976

#### **Medical Education**

Medical Doctorate  
Loyola University, Stritch School of Medicine, Chicago, Illinois, 1969-1973

Honors Program, Computers in Clinical Medicine  
Division of Computer Research and Technology, William Mohler, MD  
National Institutes of Health, Bethesda, Maryland, January -March, 1973

#### **Undergraduate Education**

B.S. Degree in Biological Sciences (Minor in Computer Science, Biostatistics)  
University of California, Irvine, Irvine, California, 1965 – 1969

Honors Program Statistics in the Health Sciences-Eleventh Summer  
Program National Institutes of Health, University of Washington, Seattle, 1969

**Secondary Education**

Santa Ana Valley High School, Santa Ana, California, 1962 – 1965

Exchange Student, American Field Service, Neues Gymnasium, Göttingen, Germany, 1964 - 1965

**BOARD CERTIFICATION**

---

National Board of Medical Examiners, 1974

American Board of Ophthalmology, 1977

**LICENSURE**

---

California, Issued 1976

**ACADEMIC APPOINTMENTS/PROFESSIONAL POSITIONS**

---

Attending Physician, Ophthalmology Section

Hines Veterans Administration Hospital, Hines, Illinois, 1976-1977

Clinical Instructor, Ophthalmology

Eye and Ear Infirmary, University of Illinois, Chicago, Illinois, 1976-1977

Clinical Instructor, Ophthalmology

Loyola University Medical Center, Chicago, Illinois, 1976-1977

Assistant Professor, Ophthalmology, University of California, Irvine

Irvine, California, 1978-1979

Attending Physician, Ophthalmology

Long Beach Veterans Administration Hospital, Long Beach, California, 1979-1998

Associate Clinical Professor, Ophthalmology

University of California, Irvine, Irvine, California, 1992- 2013

Teaching Faculty, Alcon Surgical, 1990-2010

Medical Director, Orange County Diabetes Resource Center, St. Joseph Hospital, Orange, California, 2015 -

Present

## **PROFESSIONAL SOCIETY MEMBERSHIPS**

---

- 1977-Present      The Macula Society, Founding Member
- 1979-Present      American Academy of Ophthalmology, Fellow
- 1973-1995          Association for Research in Vision and Ophthalmology
- 1973-1994          American Medical Association
- 1976-1990          International Society for Clinical Electrophysiology in Vision
- 1979-Present      California Medical Association
- 1979-Present      Orange County Medical Association
- 1978-Present      California Academy of Eye Physicians and Surgeons
- 1978-Present      Orange County Society of Ophthalmology  
Member, 1978  
Assistant Program Chairman, 1980  
Program Chairman, 1981  
Secretary, 1982  
Treasurer, 1983  
Vice President, 1984  
President, 1985
- 1989-2013          American Diabetes Association California Affiliate, Orange County Chapter  
Board Member, 1989-1991  
Patient Education Committee, 1989-1996  
American Association of Diabetes Educators, 1994-2004
- 1994-Present      American Society of Retina Specialists (The Vitreous Society)

## **HOSPITAL STAFF AFFILIATIONS**

---

- 2015-Present      Orange County Global Medical Center, Santa Ana, California
- 1980-Present      Hoag Memorial Hospital Presbyterian, Newport Beach, California

## PROFESSIONAL PRESENTATIONS

---

01. *The Electro-Oculogram in Response to Near UV and Near IR Light*  
Association for Research in Vision & Ophthalmology, Sarasota, Florida; April 1975
02. *Ocular Findings Associated with Iq+ Chromosomes*  
Association for Research in Vision & Ophthalmology, Portland, Oregon; September 1975
03. *Eye Injuries*  
Northern Illinois Association of Industrial Nurses, Chicago, Illinois; October 1975
04. *The Exacerbation of Behcet's Syndrome by Ingestion of English Walnuts*  
Association for Research in Vision & Ophthalmology, Sarasota, Florida; April 1976
05. *Rod-Cone Dystrophy and Nanophthalmos*  
Association for Research in Vision & Ophthalmology, Sarasota, Florida; April 1977
06. *Rod-Cone Dystrophy and Alopecia Areata Universalis*  
International Society for Clinical Electoretinography, Ghent, Belgium; June 1977
07. *The Fundus as a Window to Systemic Diseases*  
The Medical College of Wisconsin, Department of Internal Medicine, Lecture Series, Milwaukee, Wisconsin; September 1977
08. *Electrophysiologic Changes in Juvenile X-Linked Retinoschisis*  
Association for Research in Vision & Ophthalmology, Sarasota, Florida; May 1978
09. *A Study of the Effects of Retroseptal and Oral Corticosteroids on Serous Choroidal Detachment After Retinal Detachment Surgery*  
Ocular Drug Therapy Update '78, Newport Beach, California; September 1978
10. *Choroidal Edema, Hemorrhagic and Serous: Clinical and Experimental Correlation*  
XIth Meeting of Club Jules Gonin Society, Barcelona, Spain; October 1978  
Presentation by Thomas M. Aaberg, MD
11. *Tamoxifen Retinopathy*  
The Macula Society, Sonesta Beach, Florida; January 1979  
Presentation by Mano Swartz, MD
12. *Factors Influencing Formation of Serous Choroidal Detachment After Retinal Detachment Surgery*  
Association for Research in Vision & Ophthalmology, Sarasota, Florida; May 1979
13. *Ocular Electrophysiology*  
Western Medical Center, Santa Ana, California; August 1979
14. *A Review of the Diabetic Retinopathy Vitrectomy Study*  
Western Medical Center, Santa Ana, California; June 1981
15. *Ultrasonography of the Eye and Orbit*  
Hoag Memorial Hospital, Presbyterian, Newport Beach, California; June 1981
16. *Indications for Anterior Segment Vitrectomy*  
Phoenix Eye Society, Phoenix, Arizona; October 1981

17. *Pre-Vitrectomy Macular Function Testing*  
The Macula Society, Orlando, Florida; January 1983
18. *Opaque Media Testing--Current Concepts in Penetrating Keratoplasty*  
Western Medical Center/Orange County Eye Bank, Santa Ana, California; February 1983
19. *Understanding Diabetic Retinopathy*  
Diabetic Teaching Nurses of Southern California, Monrovia, California; September 1983
20. *Diabetic Retinopathy*  
Nursing Seminar, Western Medical Center, Santa Ana, California; May 1984
21. *Diabetes: Combating the Complications*  
Diabetes Teaching Nurses of Southern California, San Bernardino, California; October 1984
22. *Retinal Disorders*  
Braille Institute Anaheim, Instructors Conference, Anaheim, California; October 1985
23. *Mizuo-Nakamura Phenomenon in Late Onset Dominant Cone Degeneration*  
Macula Society--Eighth Annual Scientific Meeting, Marathon, Florida; February 1985  
Presentation by John Heckenlively, M.D.
24. *Macular Degeneration*  
Invited Speaker. Medical Society of Leisure World; April 15, 1990
25. *Diabetic Retinopathy-The Message and Challenge of Diabetes 2000*  
Invited Speaker. Hawaiian Eye Foundation, Maui, Hawaii; January 25, 1991
26. *Diabetic Retinopathy*  
Operating Room Nurses Presentation. Hoag Memorial Hospital Presbyterian, Newport Beach, California; June 26, 1991
27. *Laser Indirect Ophthalmoscopy*  
American College of Surgeons, Palm Springs, California; January 1992
28. *Diabetic Retinopathy*  
Invited Speaker. Medical Society of Leisure World; April 15, 1992
29. *Intraocular Pressure Swings During Closed Pars Plana Vitrectomy Surgery*  
American College of Surgeons, Annual Meeting So. Calif. Chapter, Santa Barbara, California; January 24, 1993
30. *Intraocular Pressure Swings During Closed Pars Plana Vitrectomy Surgery*  
Advanced Vitreoretinal Symposium in Honor of Thomas Aaberg M.D., Medical College of Wisconsin, Kohler, Wisconsin; April 17, 1993
31. *Infrared Laser Indirect for Retinopathy of Prematurity*  
Invited Speaker. American College of Surgeons, Annual Meeting So. Calif. Chapter, Hyatt Hotel, Newport Beach; January 22, 1994
32. *Ultrasonographic and Physiologic Opaque Media Testing*  
Invited Lecture to UCI Residents. University of California, Irvine, Department of Ophthalmology; March 16, 1994

33. *Putting the Patient First and Surviving Bureaucratic Nonsense*  
Invited Speaker Commencement Address to Graduating Residents. University of California, Irvine, Department of Ophthalmology; June 15, 1994
34. *Opaque Media Testing & Laser Indirect Treatment of Retinopathy*  
Invited Speaker. Orange County Optometric Society, Ocular Pathology Symposium '94 Western Medical Center-Bash Auditorium, Santa Ana, California; August 28, 1994
35. *Practical Considerations and Advances In Vitreo-Retinal Diseases*  
Invited Speaker. Ocular Pathology Symposium '96, Orange County Optometric Society, Irvine Medical Center, California; August 18, 1996
36. *Advanced Phaco Techniques for Best Demonstrated Outcomes: Retinal Surgeon's View of Cataract Complications*  
Alcon Ophthalmic Symposium, Newport Beach, California; Sept. 20-22, 1996
37. *Advanced Phaco Techniques for Best Demonstrated Outcomes: Posterior Segment Complications - What the Anterior Surgeon Should Not Do*  
Featured Speaker, Alcon Ophthalmic Symposium, Newport Beach, California; September 21, 1996
38. *Opaque Media Testing & Retinal Dystrophies*  
Invited Lecture to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 26, 1997
39. *Opaque Media Testing*  
Invited Lecture to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 11, 1998
40. *Understanding Medical Savings Accounts-Putting the Patient First*  
American College of Surgeons, Rancho Mirage, California; January 31, 1998
41. *Opaque Media Testing*  
Invited Lecture to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 11, 1998
42. *Intraocular Pressure During Posterior Vitrectomy Surgery*  
Western Retina Study Club, Tenth Annual Meeting, San Francisco, California; March 16-17, 1998
43. Western Retina Study Club Eleventh Annual Meeting Newport Beach, California; March 12-13, 1999
44. *Macular Retinal Disease Identification and Progression*  
Ophthalmic Photographers' Society Mid-Year Meeting, Jules Stein Eye Institute, University of California, Los Angeles; June 25, 1999
45. *Plaquenil Maculopathy - A Review of Diagnosis and Management*  
American College of Surgeons Annual Scientific Meeting, Huntington Beach, California; January 23, 2000
46. *Retina Related Medical Malpractice*  
Invited Speaker. American College of Surgeons Annual Scientific Meeting, Santa Barbara, California; January 21, 2001
47. *Angioid Streaks: Macular Hemorrhages from Indirect Trauma in a Patient with PXE without Pre-Existing Macular Breaks*  
Macula Society 27<sup>th</sup> Annual Meeting, Las Vegas, Nevada; February 25-28, 2004

48. *The Great Debates: Controversies in Retinal Disease 2005*  
Invited Participant. Medical Education Seminar, University of California, Irvine, Beckman Laser Center, Irvine, California; March 26, 2005
49. *Update on Wet Macular Degeneration*  
Invited Participant. International Academy of Low Vision Specialists, San Diego, California; November 5, 2011
50. *Referral of Low-Vision Patients by Retina Specialist*  
Invited Participant. International Academy of Low Vision Specialists, San Diego, California; November 5, 2011
51. *Retina Psychophysiological Diagnostic Testing*  
Retina Care Symposium, Costa Mesa, California; December 5, 2013
52. *Retina-related Malpractice*  
Retina Care Symposium, Costa Mesa, California; December 5, 2013
53. *Case Presentation. Use of Visual Physiology Testing to Separate True from Fictitious Visual Loss*  
Retina Clinical Exchange for Orange County Ophthalmologists, Newport Beach, California; March 20, 2014
59. *Diabetic Macular Edema: Case Studies*  
Multidisciplinary Approach for Management of Patients with Diabetic Macular Edema, Irvine, California; September 10, 2014
60. *Intraocular Pressure Estimates Measured Using a Novel Handheld Tonometer (Poster)*  
Davey PG, **Maggiano JM**, Peterson, LC, Maurath S, Joson P. Association for Research in Vision and Ophthalmology, 2019 Annual Meeting, Vancouver, BC, Canada.

## PROFESSIONAL EXPERIENCE

---

Establishment and directorship of retinal function testing laboratory, Loyola University Hospital, Chicago, Illinois in 1974; Consultation service through 1977.

Monthly Lecturer, Physiology of the Retina Seminar, Loyola University Medical Center, Chicago, Illinois, 1975-1977

Participation in F.O.C.U.S. program, Eye Clinic, Port-du-Paix, Haiti, March 1976

Director and lecturer, monthly fluorescein angiography seminar, Eye Institute, The Medical College of Wisconsin, Milwaukee, Wisconsin, 1977-1978

Establishment of ultrasound testing, Eye Clinic, Long Beach Veterans Administration Hospital, Long Beach, California, 1978

Establishment of Vitrectomy Surgery Unit, Long Beach Veterans Administration, Hospital, Long Beach, California, 1978

Establishment of Ocular Ultrasonography Unit, University of California, Irvine Medical Center, Orange, California, 1978

Ultrasonography and Retina Clinic, University of California, Irvine, Medical Center, Orange, California, 1978-1980

Ultrasonography and Retina Clinic, Long Beach Veterans Administration Hospital, Long Beach, California; 1978 – 1996

Director of Retinal Physiology, Western Medical Center, Santa Ana, California, 1979 – 1998

Medical Director, Ophthalmology Laboratory, Hoag Memorial Hospital Presbyterian, Newport Beach, California, 1988 - 1993

Medical Director, Ophthalmology Laboratory, Western Medical Center, Santa Ana, California, October 1990 - 1998

Participant, Vitreoretinal Advisory Council, Alcon Laboratories, Inc.-Irvine, California, Laguna Hills, California; April 11-14, 1991

Alcon Retina Advisory Council, Annual Meeting, Monterey, California, March 25 - 27, 1994

Medical Director, Retinal and Visual Physiology Laboratory, Orange County Retina Medical Group, Santa Ana, California, 1996-Present

Alcon Laboratories, Inc., Executive Conference and Tour, ACCURUS™ Model Research, Irvine Technology Center, Irvine, California; July 30, 1998

Retinal Advisory Council Symposium, Alcon Laboratories, Inc., Texas, Vitreoretinal Surgery Technology & ACCURUS™ Model Research, Napa Valley, California; August 6-8, 1998

Retinal Advisory Council Symposium, Alcon Laboratories, Inc., Palm Beach, Florida; May 10 – 12, 2002

Retinal Advisory Council Symposium, Alcon Laboratories, Inc., Nantucket, Massachusetts; June 20 – 22, 2003

## **COURSES DIRECTED**

---

Basic Vitrectomy Course/Lab and Lecture Sessions, Western Medical Center, Santa Ana, California; October 26 & 27, 1979

Anterior Segment Ocutome/Fragmatome, System Symposium and Workshop, Hoag Memorial Hospital, Presbyterian, Newport Beach, California; May 6 & 7, 1983

Practical Methods in Diabetes Management, 1st Annual Meeting, Westin South Coast Plaza, Costa Mesa, California; November, 1990

Practical Methods in Diabetes Management, 2nd Annual Meeting, Newport Beach, CA; November 1 & 2, 1991

## **2015 PROFESSIONAL MEETING ATTENDANCE/COURSEWORK**

---

American Academy of Ophthalmology, Las Vegas, Nevada; November 13-17, 2015  
2015 Subspecialty Day: 14 Credits (Retina)  
2015 AAO: 27 Credits  
Total Credits: 41 hrs



## PUBLIC PRESENTATIONS

---

01. Research Approaches and Advances in Retinitis Pigmentosa and Related Diseases  
National Retinitis Pigmentosa Foundation, Chicago, Illinois; May 1977
02. *Retinitis Pigmentosa and Related Diseases* National Retinitis Pigmentosa Foundation  
Western Medical Center, Santa Ana, California; February 1980
03. *Diabetes and the Eye*  
American Diabetes Association, Orange County Chapter, Anaheim Convention Center, Anaheim, California; May 1982
04. *Diabetic Retinopathy*  
Diabetes Outreach Program, Eisenhower Medical Center, Palm Springs, California; April 1984
05. *History of Vitrectomy Surgery*  
Featured Speaker. Alcon National Engineering and Sales Meeting, Newport Beach; February 1990
06. *Beyond the Basics: Diabetes and The Eye*  
Seminar Director and Lecturer. American Diabetes Association-Orange County Chapter, Western Medical Center, Santa Ana, California; October 27, 1990
07. *Eye Complications in Diabetes*  
Orange Aid, Orange Association of Diabetes Educators, Fullerton, California; April 17, 1991
08. *Beyond the Basics - Diabetes and the Eye*  
American Diabetes Association, Saddleback Memorial Hospital, Laguna Hills, California;  
March 21, 1992
09. *New Technologies of Laser Indirect Ophthalmoscopy Systems*  
Invited Speaker. Nidek National Sales & Engineering Meeting, Carmel Highlands Resort, San Diego, California; April 9, 1992
10. Invited Speaker with Patrick Farrell M.D., Charles W. Skoien, Jr., Consultant, Community Residential Care Association of California; November 1992
11. Lecture. Sun Valley High School (Bruce Peterson, Chief Science Teacher); February 2, 1993
12. *Complications In the Eye As A Result of Diabetes*  
Invited Speaker. American Diabetes Association-Orange County Chapter, Pump Group, Western Medical Center, Santa Ana, California; May 11, 1993
13. *Fibromyalgia and the Eyes*  
Invited Speaker. One on One Fibromyalgia Support Group (Karen Brooks, Executive Director), Hoag Conference Center, Newport Beach, California; October 25, 1993
14. *Ophthalmology and Diabetes*  
Invited Speaker. American Diabetes Association-Los Angeles Chapter, Pump Group, 5th Annual Diabetes Faire, Long Beach Memorial Medical Center, Long Beach, California; November 6, 1993
15. *Diabetic Retinopathy: The Importance of Blood Sugar Control*  
St. Joseph Hospital-ADA Support Group, Orange Senior Center, Orange, California; January 3, 1995

16. *Importance of Diabetic Control in Diabetic Retinopathy*  
Project Health, Saddleback Memorial Hospital Medical Center, Laguna Hills, California;  
January 24, 1995
17. *Diabetes Control: Lookin' Good*  
Patient Education Seminar, American Diabetes Association, Irvine Marriott, Irvine, California;  
June 25, 1995
18. *Fibromyalgia and the Eyes*  
Invited Speaker. One on One Fibromyalgia Support Group, Hoag Hospital Conference Center, Newport Beach, California; February 26, 1996
19. *Diabetes and Eye Disease*  
Invited Speaker. Costa Mesa Senior Center, Costa Mesa, California; March 8, 1999
20. *Diabetic Retinopathy*  
Invited Speaker. American Diabetes Association-Orange County Chapter, Western Medical Center, Santa Ana, California; October 1, 1996
21. *Macular Degeneration*  
Guest Speaker. Costa Mesa-Orange Coast Lions Club, Costa Mesa, California; November 21, 1996
22. *Medical Savings Accounts - Why Consumers are Demanding This Choice*  
Spring Symposium. St. Joseph Hospital, Invited Speaker, April 26, 1997
23. *Medical Savings Accounts*  
Invited Speaker. Columbia West Anaheim Medical Center, Anaheim, California; December 5, 1997
24. *The Retina and Uveitis in Fibromyalgia and Related Disorders*  
Invited Speaker. American Fibromyalgia Foundation, Newport Beach Marriott, Newport Beach, California; February 28, 1998
25. *Visual Disability: Technical Explanation of Current Definitions in C.F.R. section 20*  
Invited Speaker. Orange County Bar Association, Social Security Disability Attorneys, Orange, California; September 18, 1998
26. *HMO's/Managed Care: A Medical/Legal Slight of Hand*  
Speaker and Panelist. Orange County Trial Lawyers Association & Forensic Expert Witness Association Joint Symposium, Antonello's Ristorante, Santa Ana, California; February 18, 1999
27. *Diabetic Retinopathy*  
Invited Speaker. Orange County Insulin Pump Group, Western Medical Center, Santa Ana, California; April 6, 1999
28. *How Diabetes Affects Vision?*  
Invited Speaker. Hoag Memorial Hospital Presbyterian, Diabetic Support Group ("Naturally Sweet"), Newport Beach, California; May 10, 2000
29. *The Retina: Diseases & Current Research for a Cure*  
City of Irvine, Senior Outreach Program, Lakeview Senior Center, Irvine, California; September 28, 2000
30. *Macular Degeneration: New Treatments*  
Invited Speaker. L.A. Royal Vista Country Club, Rotary Club Meeting, Walnut, California; October 3, 2000

31. *Billing, Collection, Scheduling, & Time Management*  
Speaker and Panelist. Forensic Expert Witness Association, Irvine, California; October 30, 2000
32. Commencement Address  
Oakridge Private School (Directors: Mr. & Mrs. Fred Burry), Irvine, California; June 8, 2001
33. *Diabetic Retinopathy*  
Invited Speaker. Orange County Insulin Pump Group, Western Medical Center, Santa Ana, California; September 3, 2002
34. *Diabetes and Eye Disease*  
Invited Speaker. Costa Mesa Senior Center, Costa Mesa, California; October 8, 2004
35. *Diabetic Retinopathy*  
St Joseph Hospital Diabetes Support Group/Diabetics United of Orange County, Orange, California; March 3, 2009
36. *Ophthalmology/Retina Career*  
Career Day Presentation, MacArthur Intermediate School, Santa Ana, California; March 25, 2009
37. *Retinal Physiology*  
Orange County Diabetes Resources Organization, California; December 3, 2013
38. *Blurred Vision and Diabetes*  
St Joseph Hospital Diabetes Support Group/Diabetics United of Orange County, Orange, California; December 1, 2015

#### **BUSINESS, MANAGED CARE COURSES & EXPERIENCE**

---

01. *Empowering Your Office Manager/Successful Challenging of Medicare Denials*  
Ophthalmology Department-University of California, Irvine, Irvine, California; December 4, 1993
02. *Planning, Contracting & Negotiating with Managed Care*  
Specialty Capitation & Risk Sharing Seminar, Institute for International Research, Coral Gables, Florida; December 6 - 8, 1995
03. *Planning, Contracting & Negotiating with Managed Care*  
Irwin Professional Seminar, Business Network; March 28, 1996
04. Irwin Professional Seminar  
Business Network, University of California, Los Angeles, Jules Stein Eye Institute, Los Angeles, California; March 28, 1996
05. Irwin Professional Seminar  
Business Network, University of California, Los Angeles, Jules Stein Eye Institute, Los Angeles, California; April 12 & 13, 1996

## CONSULTANT/CLINICAL TRIALS

---

01. Alcon Retinal Advisory Council, Irvine, California, 1990 - 2010
02. Wyeth-Ayerst Pharmaceutical, 1990 - 1993  
Principal Investigator. *The safety and efficacy of Tolrestat in the treatment of diabetic retinopathy*
03. Mini Med, Retinal Consultant, National and International Trials, 1990 - 2001
04. Chiron Ophthalmics, Retinal Consultant; 199-1992
05. Innerspace, Intraocular Pressure Transducer Project, Irvine, California; 1991-1994
06. Allergan Medical Optics; May 1995-October 1995  
Intraocular Lens Research Project, Rabbit Model of Array Multifocal Intraocular Lens  
Director of Research: Nicholas Tarantino, O.D, Arlene Gwon M.D.  
Irvine, California
07. ACCURUS™, System Investigator, Alcon Surgical, Inc., Irvine, California; 1996 - 2000
08. California Advantage, Inc., Specialty Advisor, San Francisco, California; 1997-1998
09. Allergan Medical Optics, Irvine, California; June 4th, 1998  
Implanted Vitreous Device, new product research  
Project Discussion with medical researchers & engineers  
Director of Research: Nicholas Tarantino, O.D, Arlene Gwon M.D., Valdemar Portney, Ph.D
10. CIBA/QLT PhotoTherapeutics, Protocol #BPD-OCR-005 (VAM); 1999-1999  
Sub-Investigator. *An open-label multicenter safety study of the treatment of predominantly classic subfoveal CNV secondary AMD using PDT with verteporfin for injection*
11. Eyetech Pharmaceuticals, Protocol #EOP 1004, Phase II/III; 2001-2005  
Sub-Investigator. *A randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) in patients with exudative AMD*
12. Novartis Ophthalmics, Protocol #CBPD952A2201 (ADD-V), Phase II; 2002-2002  
Sub-Investigator. *Adjunctive Diclofenac therapy and Visudyne PDT (ADD-V): A three-month randomized, placebo-controlled, double-masked, multicenter study of the effect of adjunctive diclofenac therapy and Visudyne PDT in patients with predominantly classic subfoveal CNV secondary to AMD*
13. Alcon Research, Ltd., Protocol C-01-99, Phase III; 2002-2005  
Principal Investigator. *A multicenter, double-masked, randomized, parallel groups study to demonstrate efficacy and safety of anecortave treatment relative to Visudyne for AMD*
14. OxiGENE, Inc., Protocol MMD-213, Phase III; 2004-2006  
Sub-Investigator. *A multi-center, randomized, double-masked, placebo-controlled, parallel group, evaluation of the safety and efficacy of combretastatin A4 phosphate infusion for treating subfoveal CNV in pathologic myopia*
15. Diabetic Retinopathy Clinical Research Network/National Eye Institute, Protocol B; 2004-2009  
Sub-Investigator. *A randomized trial comparing intravitreal corticosteroids and laser photocoagulation for DME*

16. Alcon Research, Ltd., Protocol C-02-60 (AART), Phase III; 2004-2009  
Sub-Investigator. *Anecortave Acetate Risk Reduction Trial (AART): An evaluation of efficacy and safety of posterior juxtasceral administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in study "A" or study "B") at risk for developing sight-threatening CNV due to exudative AMD*
17. National Eye Institute, SCORE; 2004-2009  
Sub-Investigator. *The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE): Two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: one for CRVO and one for BRVO*
18. Lilly ICOS LLC, Protocol H6D-MC-LVGO, Phase IV Collaborative Study; 2005-2006  
Sub-Investigator. *A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of 5mg tadalafil (IC351, LY450190) and 50mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction.*
19. Alcon Research, Ltd., Protocol C0459 (IDEAA), Phase III; 2005-2007  
Principal Investigator. *A trial using anecortave acetate 15mg administered every 3 months versus anecortave acetate 15 mg every 6 months versus anecortave acetate 30 mg administered every 6 months in patients with exudative AMD*
20. Eyetech Pharmaceuticals, Protocol EOP1012, Phase IV; 2005-2007  
Sub-Investigator. *A randomized, active-controlled, double-masked, single dummy, multicenter comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen given every 6 weeks for up to 102 weeks, plus sham PDT, to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal CNV secondary to AMD*
21. Novartis, Protocol CBPD952E2202 (VERITAS), Phase IIIB; 2005-2007  
Sub-Investigator. *A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing PDT with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal CNV secondary to AMD*
22. (OSI) Eyetech, Protocol EOP1023 (LEVEL), Phase IV; 2006-2008  
Sub-Investigator. *An open label, multicenter trial of maintenance intravitreal injections of Macugen (pegaptanib sodium) given every six weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a different modality resulting in maculopathy improvement*
23. QLT Inc./RVT 002 (Registry II) (QUEST); 2006-2008  
Sub-Investigator. *Registry for QLT using Visudyne in evaluation of sequential and triple therapies*
24. Novartis, Protocol #CBPD952A2308 (DENALI), Phase IIIB; 2006-2010  
Sub-Investigator. *A 24-month randomized, double-masked, controlled, multicenter study assessing safety and efficacy of verteporfin (Visudyne) photodynamic therapy administered in conjunction with ranibizumab (Lucentis) versus ranibizumab (Lucentis) monotherapy in patients with subfoveal CNV Secondary to AMD*
25. Alimera Sciences, Protocol C-01-05-001 (FAME), Phase III; 2006-2011  
Sub-Investigator. *Fluocinolone Acetonide in Diabetic Macular Edema (FAME): A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with DME (Medidur®)*

26. Regeneron, Protocol VGFT-OD-0605 (VIEW 1), Phase III; 2006-2011  
Sub-Investigator. *C*linical *E*valuation of *A*nti-angiogenesis in the *R*etina - *I*ntravitreal *T*rial 3 (*CLEAR-IT 3*): A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with neovascular AMD
27. Opko, Protocol ACU-301 (COBALT), Phase III; 2007-2009  
Sub-Investigator. *C*ombining *B*evasirinib and *L*ucentis *T*herapy (*COBALT*): A randomized, double-masked, parallel-assignment study of intravitreal bevasirinib sodium, administered every 8 to 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with exudative AMD
28. Allergan, Protocol 206207-012, Phase III; 2007-2010  
Sub-Investigator. A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700 ug dexamethasone posterior-segment drug delivery system (*DEX PS DDS*) Applicator System in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse DME
29. Vitreoretinal Technologies, Inc., Protocol PVD-301, Phase III; 2007-2010  
Sub-Investigator. A safety and efficacy study of Vitreosolve for ophthalmic intravitreal injection for inducing posterior vitreous detachment in subjects with NPDR
30. Merck & Co., Protocol 007-01, Collaborative Study; 2008-2009  
Sub-Investigator. A safety follow-up study of patients previously exposed to MK-0634 (a beta-3 receptor antagonist developed for the treatment of overactive bladder). Subjects had previously been enrolled in a multicenter, double-blind, randomized, placebo-controlled, parallel group, dose-ranging study of L-000796568 in postmenopausal women with OAB
31. Allergan, Protocol 206207-019-00, Phase II; 2008-2010  
Sub-Investigator. A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in conjunction with Lucentis® in the treatment of patients CNV secondary to AMD
32. Ophthotech Corp., Protocol OPH3000, Phase 1; 2008-2010  
Sub-Investigator. An ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetic profile of multiple intravitreal injections of volociximab ( $\alpha 5\beta 1$  integrin antagonist) as monotherapy or in combination with Lucentis 0.5 mg/eye in subjects with neovascular AMD
33. Regeneron, Protocol VGFT-OD-0706 (DA VINCI) , Phase III; 2008-2011  
Sub-Investigator. A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-eye in patients with DME
34. NEI/Tufts Medical Center, The Family Study of Macular Degeneration; 2009-2010  
*The goal is to evaluate genetic and non-genetic risk factors for AMD*
35. Allergan, Protocol 206207-018-00, Phase II; 2009-2010  
Sub-Investigator. A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in the treatment of vitrectomized subjects with DME
36. Grunenthal, Protocol KF0151Y/10, Phase IIb, Collaborative Study; 2009-2011  
Sub-Investigator. A randomized, multicenter, double-blind, parallel-group trial to assess the analgesic efficacy and safety of a new analgesic compared with placebo in subjects with painful diabetic peripheral neuropathy

37. Endo Pharmaceuticals, Protocol EN3324-201, Phase IIB, Collaborative Study; 2010-2011  
Sub-Investigator. *A randomized, multicenter, double-blind, two-arm, multicenter, placebo-controlled study to assess the efficacy and safety of EN3324 (Axomadol) in subjects with moderate to severe chronic low back pain*
38. GlaxoSmithKline, Protocol MD 7110852, Phase IIB; 2009-2012  
Sub-Investigator. *A Phase dose-ranging study of pazopanib eye drops vs. ranibizumab intravitreal injections for the treatment of neovascular AMD*
39. Genentech, Protocol FVF4579g (HARBOR), Phase III; 2009-2012  
Sub-Investigator. *A, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal neovascular AMD*
40. Lux Biosciences, Inc., Protocol LX211-11, Phase III; 2011-2013  
Sub-Investigator. *A multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of Voclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-uveitis*
41. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA; 2011-2015  
Sub-Investigator. *A multicenter, masked, randomized, comparator-controlled study evaluation of Isonep™ (sonepcizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to age-related macular degeneration*
42. Alimera Sciences, Protocol C-01-11-008 (FAME), Extension Study; 2011-2013  
Sub-Investigator. *An open-label, multicenter, extension study of the safety and utility of the new inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien® in subjects with DME*
43. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III, 2012-2013  
Sub-Investigator. *A prospective, multi-center, randomized, double-masked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*
44. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II, 2012-2013  
Sub-Investigator. *An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema*
45. Xoma, Protocol X052130/CL3-78989-005 (EYEGUARD™ -A), Phase III, 2012-2015  
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis*
46. Pfizer, Protocol B1181003-1050 (DREAM), Phase II, 2012-2013  
Sub-Investigator. *A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration*
47. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD™ -C), Phase III, 2012-2015  
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment*

48. Regeneron, Protocol VGFTe-AMD-1124 (RE-VIEW), Phase IV, 2012-2015  
Sub-Investigator. *Rigorous evaluation of vision and safety with intravitreal aflibercept injection dosed every 8 weeks over 2 years in neovascular AMD*
49. Merck, Protocol MK8931-017 (SCH 900931, P07738) (EPOCH), Phase 2/3, Collaborative Study, 2012-Present  
Ophthalmology Investigator. *A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease*
50. Ophthotech, Protocol OPH1003 (ECLIPSE), Phase III, 2013-2017  
Sub-Investigator. *A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista™ (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular macular degeneration*
51. Allergan, Protocol GMA-OZU-13-598 (ECHO), Retrospective Registry, 2013-2014  
Sub-Investigator. *A retrospective data collection study in patients receiving anti-VEGF injections for retinal vein occlusion or diabetic macular edema*
52. Aerpio, Protocol AKB-9778-CI-2003 (TIME 2), Phase II, 2014-2015  
Sub-Investigator. *A phase 2, randomized, active-controlled, double-masked, multicenter study to assess the safety and efficacy of daily subcutaneous AKB-9778 administered for 3 months, as monotherapy or adjunctive to ranibizumab, in subjects with diabetic macular edema*
53. Xoma, Protocol X052132 (EYEGUARD™ -E), Phase III, 2014-2016  
Sub-Investigator. *An open-label, non-randomized, single-arm, roll-over study to continue dosing of gevokizumab in non-infectious intermediate, posterior, or pan-uveitis patients who each successfully completed either the X052130 or the X052131 study*
54. Merck, Protocol MK8931-019 (APECS), Phase III, Collaborative Study, 2014-Present  
Ophthalmology Investigator. *A phase III, randomized, placebo-controlled, parallel-group, double blind clinical trial to study the efficacy and safety of MK8931 (SCH900931) in subjects with amnesic mild cognitive impairment due to alzheimer's disease (Prodromal AD)*
55. National Eye Institute, SCORE2, Phase III, 2014-2016  
Sub-Investigator. *A multicenter, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks*
56. Allergan, Protocol #150998-004 (PALM), Phase II, 2014-2015  
Sub-Investigator. *Evaluation of abicipar pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema*
57. Thrombogenics, Protocol #TG-MV-018 (ORBIT), Prospective Registry, Phase IV, 2014-2016  
Sub-Investigator. *Ocriplasmin Research to Better Inform Treatment*
58. Thrombogenics, Protocol #TG-MV-022 (OZONE), Retrospective Registry, Phase IV, 2014-2015  
Sub-Investigator. *Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study*
59. Allergan, Protocol #GMA-US-EYE-0272 (REINFORCE), Prospective Registry, Phase IV; 2014-2016  
Sub-Investigator. *The Ozurdex Diabetic Macular Edema Patient Registry*



60. Hoffmann-La Roche, Protocol #GX29176 (CHROMA), Phase III; 2014-2018  
Sub-Investigator. *A randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration*
61. Xoma, Protocol X052133 (EYEGUARD™ -US), Phase III; 2015-2015  
Sub-Investigator. *A randomized-withdrawal, double-masked, placebo-controlled study of the efficacy and safety of gevokizumab in treating subjects with Behçet's disease uveitis*
62. Allegro Ophthalmics, Protocol DME-202B (DEL MAR), Phase II; 2015-2015  
Sub-Investigator. *A phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of Luminata® (ALG-1001) as compared to Avastin® and focal laser photocoagulation in the treatment of diabetic macular edema*
63. Iconic Therapeutics, Protocol IT-002 (EMERGE), Phase II; 2015-2016  
Sub-Investigator. *A phase 2, randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hI-con1™ in patients with choroidal neovascularization secondary to age-related macular degeneration*
64. Bayer, Protocol BAY 73-4506/15984 (DREAM), Phase IIa/IIb; 2015-2015  
Sub-Investigator. *A combined phase IIa/IIb study of the efficacy, safety and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age-related macular degeneration*
65. Allergan, Protocol 150998-005 (CEDAR), Phase III; 2015-Present  
Sub-Investigator. *A multicenter, randomized, double-masked, parallel-group, active-controlled study evaluating the safety and efficacy of abicipar pegol (AGN-150998) in patients with neovascular age-related macular degeneration*
66. Ophthotech, Protocol OPH1004, Phase III; 2015-2016  
Sub-Investigator. *A phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti-PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration*
67. Ophthotech, Protocol OPH1005 Phase III; 2015-2016  
Sub-Investigator. *A 24 month, phase 2a, open label, safety study of Fovista (anti-PDGF-BB pegylated aptamer) regimen administered in combination with anti-VEGF therapy (Avastin, Eylea, or Lucentis) during the induction and maintenance phase of therapy*
68. Ophthotech, Protocol OPH1006 Phase III; 2015-2017  
Sub-Investigator. *Effect of anti-VEGF agents administered on a quarterly maintenance regimen in subjects with neovascular AMD receiving anti-PDGF therapy: An 18-month, phase 2a, open-label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)*
69. Regeneron, Protocol R2176-3-AMD-1417 (CAPELLA), Phase II; 2015-2017  
Sub-Investigator. *A phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration*
70. Astellas, Protocol 8232-CL-3001 (VIDI), Phase III; 2015-2016  
Sub-Investigator. *A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema*

71. Alcon, Protocol RTH258-C001 (HAWK), Phase III; 2015-2018  
Sub-Investigator. *A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration*
72. Clearside Biomedical Protocol #CLS1001-301 (PEACHTREE), Phase III; 2015-2018  
Sub-Investigator. *A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetonide injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis*
73. Alimera, Protocol #M-01-15-004 (PALADIN), Phase IV; 2016-Present  
Sub-Investigator. *A phase IV safety study of IOP signals in patients treated with Iluvien (fluocinolone acetonide intravitreal implant) 0.19mg*
74. Arctic Diagnostics, Protocol #AMD SCI-GEN, Observational Registry, 2016-2018  
Site Investigator. *AMD study of the clinical impact of genetics*
75. ThromboGenics, Protocol #TG-MV-015 (CIRCLE), Phase II; 2016-Present  
Sub-Investigator. *phase 2, randomized, double-masked, sham-controlled, multi-centre study to evaluate the efficacy and safety of ocriplasmin in inducing total posterior vitreous detachment (PVD) in subjects with non-proliferative diabetic retinopathy (NPDR)*
76. L. Hoffmann-La Roche, Protocol #BP29647 (AVENUE), Phase II; 2016-2018  
Sub-Investigator. *A multiple-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36 week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with choroidal neovascularization secondary to age-related macular degeneration*
77. L. Hoffmann-La Roche, Protocol #BP30099 (BOULEVARD), Phase II; 2016-2017  
Sub-Investigator. *A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 36-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with diabetic macular edema*
78. Actelion, Protocol #ACT-058B301 (OPTIMUM), Phase III Collaborative Trial; 2016-Present  
Sub-Investigator. *Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis*
79. Eli Lilly, Protocol #I7X-MC-LLCF, Phase II Collaborative Trial; 2016-2018  
Ophthalmology Investigator. *Effect of LY3202626 on alzheimer's disease progression as measured by cerebral 18 F-AV-1451 Tau-PET in mild alzheimer's disease dementia*
80. Eyegate #EGP-437-006, Phase III; 2016-2018  
Sub-Investigator. *A prospective, multicenter, randomized, double-masked, positive-controlled, phase 3 clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic solution compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*
81. Clearside, Protocol #CLS1001-303 (MAGNOLIA), Phase III; 2017-2018  
Sub-Investigator. *A phase 3, randomized, masked, controlled clinical trial to study the safety and efficacy of triamcinolone acetonide injectable suspension (CLS-TA) for the treatment of subjects with macular edema associated with non-infectious uveitis*

82. Clearside, Protocol #CLS1003-301 (SAPPHIRE), Phase III; 2017-2019  
Sub-Investigator. *A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion*
83. Regenerative Patch Technologies, Protocol #RPT-14-001, Phase I; 2017-Present  
Sub-Investigator. *A phase I/IIA safety study of subretinal implantation of CPCB-RPE1 (human embryonic stem cell-derived retinal pigment epithelial (RPE) cells seeded on a polymeric substrate) in subjects with advanced, dry age-related macular degeneration (AMD)*
84. VisonCare, Protocol #IMT-TES-2016, Phase IV; 2017-Present  
Sub-Investigator. *A prospective, multicenter clinical trial of the implantable miniature telescope in pseudophakic eyes with central vision impairment associated with end-stage macular degeneration. TES Study: Telescope Exchange Study*
85. Regeneron, Protocol #VGFTe-OD-1411 "PANORAMA", Phase III; 2017-2018  
Sub-Investigator. *A phase 3, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe non-proliferative diabetic retinopathy*
86. Allergan, Protocol #VOLUMA-007 "VOLUMA" Collaborative Study, Phase IV; 2017  
Ophthalmology Investigator. *A multicenter, single-blind, randomized, parallel-group, controlled study of the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel for correction of temple hollowing*
87. Aldeyra, Protocol #ADX-102-UV-005, Phase III; 2017-Present  
Sub-Investigator. *A phase 3 randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in subjects with non-infectious anterior uveitis*

## BIBLIOGRAPHY

---

01. **Maggiano JM**, Chen P, Marchese A, Friedman A. The electro-oculogram response to near UV light. *ARVO*;1975.
02. **Maggiano JM**, Kerman R, Mullenix C. Exacerbation of Behcet's syndrome by ingestion of English walnuts. *ARVO*;1976.
03. Fishman G, Fishman M, **Maggiano JM**. Macular lesions associated with retinitis pigmentosa. *Arch Ophthalmol* 1977 May;95(5):798-803.
04. Fishman GA, **Maggiano JM**, Fishman M. Foveal lesions seen in retinitis pigmentosa. *Arch Ophthalmol* 1977 November;Vol. 95, No. 11.
05. Merin S, **Maggiano JM**, Fishman GA. Retinal sensitivity under photopic conditions in patients with retinitis pigmentosa, and carriers of the X-linked recessive form. *Metab Ophthalmol* 1978;2:225-229.
06. Sieving PA, Fishman GA, **Maggiano JM**. Corneal wick electrode for recording early receptor potentials and bright flash electro-retinograms. *Arch Ophthalmol* 1978 May;96:899-900.
07. **Maggiano JM**, Fishman GA, Evans L, Goldbaum M. Calibration error in dark adaptometer. *Arch Ophthalmol* 1978 June;Vol. 96.
08. Neuman R, **Maggiano JM**, Frenkel M. Bilateral acute anterior ischemic optic neuropathy in diabetes. *Ann Ophthalmol* 1978 November;Vol.10, No.11

09. **Maggiano JM**, Aaberg TM, Farina JF. Electrophysiologic abnormalities in juvenile x-linked retinoschisis. (Abstract) ARVO 1978.
10. **Maggiano JM**, Aaberg TM, Reeser F, Meredith TA, Kingham J. Factors influencing formation of serious choroidal detachment after retinal detachment surgery. (Abstract) ARVO 1979.
11. Aaberg T, **Maggiano JM**. Choroidal edema associated with retinal detachment repair; experimental and clinical correlation. *Modern Problems in Ophthalmology* 1979;20:6-14.
12. Gagrat D, **Maggiano JM**, Belmaker RH. Effect of neuroleptic treatment in schizophrenia on the electroretinogram, electrooculogram, and color vision. *Psychiatry Res* 1979 Jul;1(1):109.
13. McKeown C, Swartz M, Blom J, **Maggiano JM**. Tamoxifen retinopathy. *Brit J Ophthalmol* 1981;65:177-179.
14. Packer A, **Maggiano JM**, Aaberg T, Meredith T, Reeser F. Serous choroidal detachment after retinal detachment surgery. *Arch. Ophthalmol* 1983 August;Vol. 101, No. 8.
15. Schoessow D, **Maggiano JM** (Editor). To see or not to see? A patient's guide to diabetic retinopathy. Library of Congress, No. Txu 100-321, 1982; Library of Congress No. Tx1-095-946, 1983; Privately published: Feb.1983, Aug.1983, Nov. 1985, Feb.1996.
16. Arnold AC, Hepler RS, Yee RW, **Maggiano JM**, Eng LF, Foos RY. Solitary retinal astrocytoma. *Clin Path Rev* 1985 November-December;Vol. 30, No. 3, p. 173-181.
17. Ober RR, Wilkinson CP, Fiore JV Jr, **Maggiano JM**. Rhegmatogenous retinal detachment after neodymium-YAG laser capsulotomy in aphakic and pseudophakic eyes. *Am J Ophthalmol* 1986 January;101:81-89.
18. Belmaker RH, **Maggiano JM**. Effect of neuroleptic treatment in schizophrenia on the electroretinogram, electrooculogram and color vision. *Psychiatry Research* 1979 Jul;1(1):109.
19. Marchese AL, **Maggiano JM**, Friedman AH. Comparison of the human electro-oculographic response to green and near-ultraviolet stimuli. *Documenta Ophthalmologica* 1992;79:117-124.
20. Glasgow B, **Maggiano JM**. Cuterebra ophthalmomyiasis. *Am J Ophthalmol* 1995 April;Vol.119, No. 4.
21. You TT, Youn DW, Chen S, Alexandrescu B, Casiano ME, **Maggiano JM**. Unusual ocular injury by an acupuncture needle. *Retinal Cases & Brief Reports*: Spring 2014; Vol.8: Issue 2:116-119.
22. You TT, Huang CX, Chen S, **Maggiano JM**, Rathod RR, Chang E, Casiano ME. Extreme patient positioning for retinal surgery in advanced kyphosis. Submitted Aug2014 to *Retinal Cases & Brief Reports*.
23. **Maggiano JM**, Liu MMN, You TT, Chen S, Rathod RR, Chang E. Clinical case of clomiphene-induced palinopsia. Submitted for publication.
24. **Maggiano JM**, Yu MC, You TT, Chen S, Rathod RR. Retinal tear formation after whole-body vibration training exercise. Submitted for publication.